http://bioengineering.ch/assets/Bilder/Journal/Samsung_FDA/_1500xAUTO_crop_center-center_75/Samsung.jpg
1/1
Previous
Next

Samsung FDA approval

FDA approval for the world’s largest single biomanufacturing facility

Samsung FDA approval

In October 2017 our customer Samsung Biologics in Incheon, South Korea, received its first approval for the manufacture of a monoclonal antibody drug substance. The facility completed in 2015 currently is the largest single biomanufacturing facility in the world in terms of bioreactor capacity and houses five times more bioreactor capacity than Samsung Biologics’ first facility. Both facilities were built by Bioengineering AG.

Read more

http://bioengineering.ch/assets/Bilder/Journal/Samsung_FDA/_600xAUTO_crop_center-center_75/Samsung1.jpg
http://bioengineering.ch/assets/Bilder/Journal/Samsung_FDA/_600xAUTO_crop_center-center_75/Samsung-2.jpg
http://bioengineering.ch/assets/Bilder/Journal/Samsung_FDA/_600xAUTO_crop_center-center_75/Samsung-3.jpg
1/3
Previous
Next
close